Pharvaris (NASDAQ:PHVS) Short Interest Update

Pharvaris (NASDAQ:PHVS) was the target of a large increase in short interest in February. As of February 15th, there was short interest totalling 390,900 shares, an increase of 25.7% from the January 31st total of 311,100 shares. Based on an average daily volume of 64,900 shares, the short-interest ratio is currently 6.0 days. Currently, 2.3% of the company’s stock are short sold.

Wall Street Analysts Forecast Growth

Separately, JMP Securities boosted their target price on shares of Pharvaris from $46.00 to $55.00 and gave the stock a “market outperform” rating in a research report on Friday, January 31st.

Hedge Funds Weigh In On Pharvaris

A number of institutional investors have recently bought and sold shares of PHVS. Legal & General Group Plc increased its holdings in shares of Pharvaris by 11.2% during the 4th quarter. Legal & General Group Plc now owns 9,855 shares of the company’s stock valued at $189,000 after purchasing an additional 994 shares in the last quarter. Geode Capital Management LLC raised its stake in shares of Pharvaris by 3.7% during the 4th quarter. Geode Capital Management LLC now owns 38,333 shares of the company’s stock worth $735,000 after buying an additional 1,356 shares during the last quarter. Deutsche Bank AG lifted its stake in shares of Pharvaris by 13.0% during the 4th quarter. Deutsche Bank AG now owns 18,168 shares of the company’s stock worth $348,000 after purchasing an additional 2,087 shares during the period. JPMorgan Chase & Co. lifted its position in Pharvaris by 1,125.3% in the fourth quarter. JPMorgan Chase & Co. now owns 3,100 shares of the company’s stock valued at $59,000 after purchasing an additional 2,847 shares during the period. Finally, Public Employees Retirement System of Ohio acquired a new stake in Pharvaris during the third quarter valued at $57,000.

Pharvaris Trading Up 2.0 %

Pharvaris stock traded up $0.32 during mid-day trading on Friday, reaching $15.77. The company had a trading volume of 48,224 shares, compared to its average volume of 71,484. The business has a fifty day simple moving average of $17.49 and a 200 day simple moving average of $19.21. Pharvaris has a fifty-two week low of $14.14 and a fifty-two week high of $27.46. The company has a market cap of $824.35 million, a P/E ratio of -5.63 and a beta of -3.02.

Pharvaris Company Profile

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.